

INTERLEUKIN GENETICS INC  
Form 8-K  
August 10, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) August 9, 2007

**Interleukin Genetics, Inc.**

---

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

---

(State or Other Jurisdiction of Incorporation)

**001-32715 94-3123681**  
(Commission File Number) (IRS Employer Identification No.)

**135 Beaver Street  
Waltham,  
MA**      **02452**  
(Address of Principal Executive Offices) (Zip Code)

**(781) 398-0700**

---

(Registrant's Telephone Number, Including Area Code)

---

(Former Name or Former Address, if Changed Since Last Report)

Edgar Filing: INTERLEUKIN GENETICS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 2.02 Results of Operations and Financial Condition.**

On August 9, 2007, Interleukin Genetics, Inc. issued a press release to report its consolidated financial results for its second quarter ended June 30, 2007. A copy of the earnings press release is being furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(c) The following exhibit is furnished with this report:

Exhibit No.	Description
99.1	Earnings Press Release dated August 9, 2007.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Interleukin Genetics, Inc.**  
(Registrant)

Date: August 10, 2007

**/s/ THOMAS J. CURRAN, JR.**  
**Thomas J. Curran, Jr.**  
*Interim Chief Executive Officer*  
(Signature)

---